Regeneron Pharmaceuticals, Inc. Earnings

Regeneron Pharmaceuticals, Inc.’s revenue jumped 2.51% since last year same period to $3884.3Mn in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 3.46% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit fell -7.97% since last year same period to $844.6Mn in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -42.15% fall in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -10.22% since last year same period to 21.74% in the Q4 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -44.09% fall in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 9.16 - a -12.93% fall from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 9.16.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Regeneron Pharmaceuticals, Inc. declared 0.94 dividend per share during the earnings announcement for Q1 2026.